Clinical Trial

Correction of Psoriatic T Cell Signatures by Deucravacitinib

Name: Correction of Psoriatic T Cell Signatures by Deucravacitinib — clinical trial record (NCT05858645)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 4

View on ClinicalTrials.gov →

Summary

This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the Tyrosine kinase 2 (TYK2) blocker, deucravacitinib.

Trial Details

NCT Number	NCT05858645
Lead Sponsor	University of California, San Francisco Collaborators: Bristol-Myers Squibb
Conditions	Psoriasis Vulgaris
Enrollment	25 participants
Start Date	2023-10-01
Primary Completion	2028-06 (estimated)
Study Completion	2028-06 (estimated)
Updated on ClinicalTrials.gov	2026-06-04